ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 178,15
0,13%
Dow Jones
40 003,59
0,34%
DAX
18 740,17
0,18%
Brent Oil
84,11
0,62%
Bitcoin
66 725,10
0,85%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Diffusion Pharmaceuticals Inc (DFFN)

  7. Diffusion Pharmaceuticals Inc (DFFN) Actualités

DFFN

Diffusion Pharmaceuticals (DFFN)

Diffusion Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DFFN
DateHeureSourceTitreSymboleSociété
15/05/202423h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DFFNDiffusion Pharmaceuticals Inc
14/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DFFNDiffusion Pharmaceuticals Inc
10/05/202423h09Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:DFFNDiffusion Pharmaceuticals Inc
29/04/202422h06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:DFFNDiffusion Pharmaceuticals Inc
12/04/202401h55Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:DFFNDiffusion Pharmaceuticals Inc
29/03/202421h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DFFNDiffusion Pharmaceuticals Inc
06/03/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DFFNDiffusion Pharmaceuticals Inc
28/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DFFNDiffusion Pharmaceuticals Inc
09/02/202423h02Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:DFFNDiffusion Pharmaceuticals Inc
09/02/202422h31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DFFNDiffusion Pharmaceuticals Inc
29/09/202322h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DFFNDiffusion Pharmaceuticals Inc
29/09/202322h01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:DFFNDiffusion Pharmaceuticals Inc
15/08/202322h01GlobeNewswire Inc.Diffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaNASDAQ:DFFNDiffusion Pharmaceuticals Inc
14/08/202322h16Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:DFFNDiffusion Pharmaceuticals Inc
14/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DFFNDiffusion Pharmaceuticals Inc
13/07/202322h32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:DFFNDiffusion Pharmaceuticals Inc
23/06/202312h03Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
19/05/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
15/05/202323h20Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
15/05/202314h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
11/05/202312h05Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
03/04/202323h50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
30/03/202313h00GlobeNewswire Inc.EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative DiseasesNASDAQ:DFFNDiffusion Pharmaceuticals Inc
24/03/202321h06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
16/12/202223h17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
16/12/202212h30GlobeNewswire Inc.Diffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesNASDAQ:DFFNDiffusion Pharmaceuticals Inc
06/12/202214h31Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prrn14a)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
05/12/202212h30GlobeNewswire Inc.Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-DealingNASDAQ:DFFNDiffusion Pharmaceuticals Inc
23/11/202217h27Edgar (US Regulatory)Proxy Statement - Contested Solicitations (preliminary) (prec14a)NASDAQ:DFFNDiffusion Pharmaceuticals Inc
17/11/202223h19GlobeNewswire Inc.LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DFFN

Dernières Valeurs Consultées

TG
LWB
Mesoblast
BIT
F17781
Vontobel Financial Produ...
ASX
CBALOC
LSE
76FC
Int.fin.24
KOSPI
000970
Korea Castiron Pipe Ind
TG
M3C
Mitsubishi Chemical
TG
48W
Pensana
LSE
T3PM
Jpm Cl Ch S Etf
TG
ZSB
Sirona Biochem
COIN
BONKOETH
BONKTOKEN [OLD]
CCOM
US100
US Tech 100
EU
BUNS
Amundi Index Solutions
TG
RHK
Rhoen Klinikum
USOTC
ADHLF
Applied Development (PK)
BIT
P1ZY11
NLBNPIT1ZY11 20351221 53...
UNSW3
GRMTKETH
Gramatik
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés